Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.400 Biomarker group BEFREE Ectopic hTERT expression immortalized normal mesothelial cells and a premalignant, p16(INK4a)-negative keratinocyte line. 10648628 2000
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.400 PosttranslationalModification group BEFREE Eight of 21 patients (38%) had p16 promoter hypermethylation and 9p21 LOH, including 3 patients who had only premalignant Barrett's epithelium. 9205067 1997
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.400 Biomarker group BEFREE Expression of p16(INK4a) may aid in the diagnosis of HPV-related lesions and as such may be of value as a surrogate marker in the diagnosis of vulvar premalignant and malignant lesions. 15870532 2005
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.400 Biomarker group CTD_human Hypermethylation-induced transcriptional silencing of MGMT and p16 genes in both precancer and cancer suggests important role of these changes in progression of premalignant state to malignancy. 24991542 2014
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.400 Biomarker group BEFREE Hypermethylation-induced transcriptional silencing of MGMT and p16 genes in both precancer and cancer suggests important role of these changes in progression of premalignant state to malignancy. 24991542 2014
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.400 Biomarker group BEFREE Loss of heterozygosity (LOH) at 9p21 and 17p13 chromosomes (locations for p16 and p53 genes, respectively) is frequently observed in the premalignant condition, Barrett's esophagus. 10601379 1999
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.400 GeneticVariation group BEFREE Mutation, promoter hypermethylation and loss of heterozygosity involving the tumor suppressor gene p16 (CDKN2a/INK4a) have been detected in a wide variety of human cancers, but much less is known concerning the frequency and spectrum of p16 mutations in premalignant conditions. 19043591 2008
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.400 GeneticVariation group BEFREE No p16 point mutations have been found in premalignant or CIS lesions. 11820618 2001
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.400 AlteredExpression group BEFREE Only two premalignant lesions showed absence of p16 expression, of which one (carcinoma in situ) was hypermethylated at the p16(INK4a) promoter region and the other (severe dysplasia) showed BMI-1 expression. 15892997 2005
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.400 AlteredExpression group BEFREE p16(INK4A) immunohistochemical overexpression in premalignant and malignant oral lesions infected with human papillomavirus. 14500697 2003
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.400 Biomarker group BEFREE Promoter methylation of the death-associated protein kinase and p16 gene has been found in about 55% and 30% cases of head and neck squamous cell carcinoma respectively but has not yet been analyzed in cutaneous premalignant and malignant lesions. 12861061 2003
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.400 Biomarker group BEFREE Significance of DNA Replication Licensing Proteins (MCM2, MCM5 and CDC6), p16 and p63 as Markers of Premalignant Lesions of the Uterine Cervix: Its Usefulness to Predict Malignant Potential 29373905 2018
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.400 Biomarker group BEFREE The high frequency of mutation, deletion, and promoter silencing of the gene encoding p16(INK4A) (p16) in premalignant dysplasias and squamous cell carcinomas (SCC) of epidermis and oral epithelium classifies p16 as a tumor suppressor. 12875969 2003
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.400 AlteredExpression group BEFREE The results revealed that nuclear expression of beta-catenin, p16 and c-myc was quantitatively increased from normal mucosa to premalignant adenoma, primary carcinoma and lymph node metastatic carcinoma; the frequency of nuclear overexpression of beta-catenin and p16 in lymph node metastases was significantly higher than that in distant metastases (p < 0.05). 14601048 2003
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.400 Biomarker group BEFREE This study analyzed 95 cases of benign and premalignant cervical glandular ACIS lesions for p16 antigen and the proliferative marker Ki-67; HPV E6/E7 transcripts were detected by RNA/RNA in situ hybridization. 12378514 2002
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.400 Biomarker group BEFREE We evaluated chromosomal instability in premalignant Barrett's esophagus tissue using high resolution Affymetrix mapping 100K SNP arrays as patients progressed through three molecular stages of disease-CDKN2A(LOH) only, CDKN2A(LOH)/TP53(LOH), and CDKN2A(LOH)/TP53(LOH) with aneuploidy. 17330261 2007
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.400 Biomarker group BEFREE We have previously identified a rare subpopulation of variant human mammary epithelial cells (vHMEC) with repressed p16INK4A that exist in disease-free women yet display premalignant properties, suggesting that they have engaged the process of malignant transformation. 19995452 2009
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.400 GeneticVariation group BEFREE We have screened a panel of 26 oral squamous cell carcinomas (OSCC), nine premalignant and three normal oral tissue samples as well as eight established OSCC cell lines for mutations in the p16/MTS1 gene. 10389982 1999